Lynparza granted orphan drug designation in Japan for BRCA-mutated metastatic pancreatic cancer
Designation based on the Phase III POLO trial that showed Lynparza nearly doubled the time patients lived without disease progression vs. placeboAstraZeneca today announced that Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer. Lynparza is co-developed and co-commercialised with MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada). The Japanese Ministry of Health, Labour and Welfare grants ODD to medicines intended